IL17A and inflammatory bowel disease: Their manuscript describes different miniproteins targeting IL-23R and IL-17A, which are well-established molecular targets in autoinflammatory diseases, including psoriasis and IBD.2,3 Miniproteins have several advantages over monoclonal antibodies.